Bridgecreek Investment Management LLC Purchases 2,675 Shares of Edwards Lifesciences Corporation (EW)

Bridgecreek Investment Management LLC grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,970 shares of the medical research company’s stock after purchasing an additional 2,675 shares during the quarter. Bridgecreek Investment Management LLC’s holdings in Edwards Lifesciences Corporation were worth $4,916,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Edwards Lifesciences Corporation by 2.0% during the 2nd quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock worth $2,453,311,000 after acquiring an additional 406,901 shares during the last quarter. BlackRock Inc. grew its position in Edwards Lifesciences Corporation by 0.8% during the 2nd quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock worth $1,668,309,000 after acquiring an additional 105,819 shares during the last quarter. Bank of New York Mellon Corp grew its position in Edwards Lifesciences Corporation by 161.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after acquiring an additional 3,277,726 shares during the last quarter. American Century Companies Inc. grew its position in Edwards Lifesciences Corporation by 7.0% during the 3rd quarter. American Century Companies Inc. now owns 2,224,010 shares of the medical research company’s stock worth $243,107,000 after acquiring an additional 144,701 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in Edwards Lifesciences Corporation by 13.3% during the 2nd quarter. Wells Fargo & Company MN now owns 2,119,260 shares of the medical research company’s stock worth $250,581,000 after acquiring an additional 248,293 shares during the last quarter. Hedge funds and other institutional investors own 82.17% of the company’s stock.

In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, October 30th. The stock was sold at an average price of $101.12, for a total value of $535,936.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction on Monday, October 30th. The stock was sold at an average price of $100.93, for a total value of $3,320,597.00. The disclosure for this sale can be found here. In the last three months, insiders sold 138,580 shares of company stock valued at $15,039,844. Corporate insiders own 2.13% of the company’s stock.

Several equities analysts recently issued reports on EW shares. BMO Capital Markets restated a “buy” rating and set a $132.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. William Blair restated an “outperform” rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. Barclays PLC raised their price target on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 27th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price objective for the company in a report on Tuesday, July 18th. Finally, Royal Bank Of Canada reiterated a “buy” rating and issued a $130.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, September 1st. Seven investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $125.17.

ILLEGAL ACTIVITY NOTICE: “Bridgecreek Investment Management LLC Purchases 2,675 Shares of Edwards Lifesciences Corporation (EW)” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/11/13/bridgecreek-investment-management-llc-purchases-2675-shares-of-edwards-lifesciences-corporation-ew.html.

Edwards Lifesciences Corporation (EW) traded down $0.93 during trading on Monday, hitting $103.85. The company’s stock had a trading volume of 1,728,200 shares, compared to its average volume of 1,650,290. The company has a market cap of $22,200.00, a price-to-earnings ratio of 28.77, a price-to-earnings-growth ratio of 1.86 and a beta of 0.46. Edwards Lifesciences Corporation has a twelve month low of $81.12 and a twelve month high of $121.45. The company has a current ratio of 3.49, a quick ratio of 2.76 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.68 EPS. research analysts expect that Edwards Lifesciences Corporation will post 3.75 earnings per share for the current fiscal year.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply